Breaking News Instant updates and real-time market news.

MNTA

Momenta

$29.77

4.395 (17.32%)

, OCSL

Oaktree Specialty Lending

$5.51

0.06 (1.10%)

10:20
01/15/20
01/15
10:20
01/15/20
10:20

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Momenta (MNTA) upgraded to Overweight from Neutral at JPMorgan with analyst Eric Joseph saying the company on Monday detailed early clinical results from its Phase 1/2 study of M254 in immune thrombocytopenic purpura and the data, albeit early, support "compelling activity / relative potency" compared with conventional intravenous immunoglobulin. He believes the ITP data, or five of six patients achieving platelet response by standard criteria, give "real clinical credence to the disruptive potential" of M254. 2. Oaktree Specialty Lending (OCSL) upgraded to Overweight from Equal Weight at Wells Fargo with analyst Finian O'Shea saying that while he made the ratings change based on valuation, he continues to view Business Development Companies positively given a benign credit environment and meaningful spread to short end benchmark rates. 3. PG&E (PCG) upgraded to Buy from Neutral at Citi with analyst Praful Mehta saying the company's potential agreement with bondholders is a "big step forward." 4. Maxar Technologies (MAXR) upgraded to Neutral from Underperform at Credit Suisse with analyst Robert Spingarn saying he thinks the recently-announced MDA sale significantly de-risks the Maxar story by meaningfully reducing the likelihood of a liquidity crunch. 5. PetroChina (PTR) upgraded to Neutral from Underperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

MNTA

Momenta

$29.77

4.395 (17.32%)

OCSL

Oaktree Specialty Lending

$5.51

0.06 (1.10%)

PCG

PG&E

$12.77

0.835 (7.00%)

OGI

Organigram

$2.92

0.75 (34.56%)

PTR

PetroChina

$50.93

-0.275 (-0.54%)

  • 06

    Feb

MNTA Momenta
$29.77

4.395 (17.32%)

01/15/20
RHCO
01/15/20
NO CHANGE
Target $50
RHCO
Buy
Momenta price target raised to $50 from $29 at SunTrust
SunTrust analyst Robyn Karnauskas raised her price target on Momenta to $50, expanding the market potential for M254 in her model to peak sales of $1B vs. $600M prior assumption while increasing her probability of success for the program to 25% from 15%. The analyst adds that her model reflects the updated share count from the company's December disclosure which includes the 2.2M green shoe and also lowers the discount-rate to 12.0% from 12.5% given her increased confidence in its pipeline execution. Karnauskas keeps her Buy rating on Momenta.
01/15/20
JPMS
01/15/20
UPGRADE
Target $30
JPMS
Overweight
JPMorgan upgrades Momenta, boosts price target to $30 from $14
JPMorgan analyst Eric Joseph last night upgraded Momenta Pharmaceuticals to Overweight from Neutral with a price target of $30, up from $14. The stock in premarket trading is up 13%, or $3.39, to $28.75. The company on Monday detailed early clinical results from its Phase 1/2 study of M254 in immune thrombocytopenic purpura and the data, albeit early, support "compelling activity / relative potency" compared with conventional intravenous immunoglobulin, Joseph tells investors in a research note. He believes the ITP data, or five of six patients achieving platelet response by standard criteria, give "real clinical credence to the disruptive potential" of M254. Current Momenta share levels under-reflect the commercial potential of M254, says Joseph.
01/10/20
RHCO
01/10/20
INITIATION
Target $24
RHCO
Buy
Immunovant initiated with a Buy at SunTrust
SunTrust analyst Robyn Karnauskas initiated coverage of Immunovant (IMVT) with a Buy rating and $24 price target, saying 2020 is an FcRn data rich year and that the space has room for multiple players. The analyst says she believes Immunovant and Momenta (MNTA) have more potent anti-FcRn therapies and will likely be more effective/convenient. She believes it is not the time to pick which drug is best, and expects both companies to go up on positive data in the space, adding that there is enough skepticism still about FcRn efficacy that the current valuation for Immunovant does not reflect success or the massive potential for 1401.
01/14/20
JPMS
01/14/20
UPGRADE
Target $30
JPMS
Overweight
Momenta upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Eric Joseph upgraded Momenta Pharmaceuticals to Overweight from Neutral with a $30 price target.
OCSL Oaktree Specialty Lending
$5.51

0.06 (1.10%)

01/15/20
WELS
01/15/20
UPGRADE
Target $6
WELS
Overweight
Oaktree Specialty Lending upgraded to Overweight on valuation at Wells Fargo
Wells Fargo analyst Finian O'Shea upgraded Oaktree Specialty Lending to Overweight from Equal Weight with a price target of $6, up from $5.50. In a research note to investors, O'Shea says that while he made the ratings change based on valuation, he continues to view Business Development Companies positively given a benign credit environment and meaningful spread to short end benchmark rates. He continues to view the industry's growth as a major positive as credit is being managed in much better hands, but sees some concern over investor base and fee structure that could hold back individual names.
10/10/19
JEFF
10/10/19
INITIATION
Target $6.5
JEFF
Buy
Oaktree Specialty Lending initiated with a Buy rating at Jefferies
Jefferies analyst Kyle Joseph initiated coverage of Oaktree Specialty Lending with a Buy rating and $6.50 price target. The analyst likes the company's "strong" performance following the management transition and "successful" rotation of non-core assets to higher-quality core investments.
01/15/20
WELS
01/15/20
UPGRADE
Target $6
WELS
Overweight
Oaktree Specialty upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo analyst Finian O'Shea upgraded Oaktree Specialty Lending to Overweight from Equal Weight with a $6 price target.
07/29/19
07/29/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Domino's Pizza (DPZ) initiated with a Sell at Deutsche Bank and a Neutral at Goldman Sachs. 2. Oaktree Specialty Lending (OCSL) initiated with a Neutral at Janney Montgomery Scott. 3. Chipotle (CMG) initiated with a Conviction Buy at Goldman Sachs, while McDonald's (MCD), Starbucks (SBUX), and Shake Shack (SHAK) were initiated with a Buy, Restaurant Brands (QSR) and Yum! Brands (YUM) were initiated with a Neutral, and Wendy's (WEN) and Jack in the Box (JACK) were initiated with a Sell. 4. PepsiCo (PEP) and Coca-Cola (KO) initiated with an Overweight at Atlantic Equities. 5. Dell Technologies (DELL) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
PCG PG&E
$12.77

0.835 (7.00%)

01/15/20
SBSH
01/15/20
UPGRADE
SBSH
Buy
PG&E upgraded to Buy from Neutral at Citi
Citi analyst Praful Mehta upgraded PG&E to Buy from Neutral.
12/18/19
SBSH
12/18/19
UPGRADE
SBSH
Neutral
PG&E upgraded to Neutral at Citi after 'fatal blow' to bondholder plan
Citi analyst Praful Mehta upgraded PG&E to Neutral from Sell after the company won approval for both its settlements as Judge Montali ruled in favor of both RSAs and didn't reject the anti-competitive clauses. The decision means PG&E's "fatal blow to the bondholder plan is confirmed," according to Mehta, who said the questions will now shift to be primarily about financing and the related CPUC and governor approvals. He believes limited debt capacity will increase dilution and likely limit upside, Mehta added. With the "extreme downside scenario" now eliminated, Mehta set an $11 price target on PG&E shares.
12/23/19
BOFA
12/23/19
NO CHANGE
BOFA
PG&E step closer to bankruptcy exit, says BofA
BofA analyst Julien Damoulin-Smith says the most recent rate case settlement by PG&E brings the company a step closer to addressing the operational issues before the June bankruptcy exit deadline. The analyst still notes that the company will likely require a higher degree of spending than it did before the Chapter 11 to develop its wildfire grid resiliency and support its outsized growth.
01/15/20
SBSH
01/15/20
UPGRADE
Target $15
SBSH
Buy
PG&E upgraded to Buy from Neutral at Citi
Citi analyst Praful Mehta upgraded PG&E to Buy from Neutral with a price target of $15, up from $11. The shares closed Tuesday up 85c to $11.92. The company's potential agreement with bondholders is a "big step forward," Mehta tells investors in a research note. The "constructive negotiations" referenced in the bankruptcy court yesterday suggest a deal with bondholders is imminent, says the analyst. Mehta believes that of even if the shareholders give a concession to bondholders, the strategic value of the deal is "significant." Further, a deal would limit the power of the California governor, he adds.
OGI Organigram
$2.92

0.75 (34.56%)

01/13/20
01/13/20
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. National Energy Services (NESR) initiated with an Overweight at Barclays. 2. Cohu (COHU) initiated with a Buy at Deutsche Bank. 3. SS&C (SSNC) initiated with a Buy at BTIG. 4. Constellium (CSTM) initiated with an Outperform at Northland. 5. Organigram (OGI) initiated with an Underperform at BofA while Tilray (TLRY) and Aphria (APHA) were initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/13/20
BOFA
01/13/20
INITIATION
Target $2.5
BOFA
Underperform
Organigram initiated with an Underperform at BofA
BofA analyst Chris Carey initiated coverage of Organigram with an Underperform rating and C$2.50 price target. While he sees "a number of positives" at the company, he is being selective in his coverage of the nine cannabis stocks he rates, stating that his preference is for companies with robust balance sheets and "some control over their nearer-term destiny." The analyst added that his rating is not a call on fiscal Q1 results to be reported Tuesday, but is reflective of view on Organigram's setup for 2020.
01/15/20
RAJA
01/15/20
UPGRADE
Target $9
RAJA
Outperform
Organigram upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Rahul Sarugaser upgraded Organigram to Outperform from Market Perform with an unchanged price target of C$9.00.
01/09/20
01/09/20
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Neutral from Outperform at Baird wiht analyst Ben Kallo saying Tesla's risk/reward is more balanced following the recent stock appreciation. 2. Boeing (BA) downgraded to Hold from Buy at Berenberg with analyst Andrew Gollan saying the grounding of the 737 Max has lasted "far longer" than expected, and Boeing's decision to halt production adds uncertainty regarding the plane's restoration timing and costs. 3. Fate Therapeutics (FATE) downgraded to Market Perform from Outperform at BMO Capital with analyst Do Kim saying the "clean" iPSC safety and positive FT516 efficacy expectations are fully reflected in the shares. 4. Organigram (OGI) downgraded to Market Perform from Outperform at Raymond James. 5. Trupanion (TRUP) downgraded to Hold from Buy at Stifel with analyst Jonathan Block saying he continues to believe in the long-term story surrounding medical insurance for companion animals. However, the stock has run in a short period of time, and the competitive landscape may possibly intensify, which could exert more demands on out-year pet acquisition cost. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PTR PetroChina
$50.93

-0.275 (-0.54%)

01/15/20
FBCO
01/15/20
UPGRADE
FBCO
Neutral
PetroChina upgraded to Neutral from Underperform at Credit Suisse
Credit Suisse upgraded PetroChina to Neutral from Underperform.
01/13/20
BOFA
01/13/20
UPGRADE
BOFA
PetroChina upgraded earlier to Buy from Neutral at BofA
BofA upgraded PetroChina to Buy from Neutral.
10/10/19
LYON
10/10/19
DOWNGRADE
LYON
Outperform
PetroChina downgraded to Outperform from Buy at CLSA
10/07/19
DAIW
10/07/19
UPGRADE
DAIW
Buy
PetroChina upgraded to Buy from Outperform at Daiwa
Daiwa analyst Dennis Ip upgraded PetroChina to Buy from Outperform.

TODAY'S FREE FLY STORIES

TLGT

Teligent

$0.40

-0.0025 (-0.62%)

15:53
01/18/20
01/18
15:53
01/18/20
15:53
Conference/Events
Teligent to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AYTU

Aytu BioScience

$0.80

0.0014 (0.18%)

15:48
01/18/20
01/18
15:48
01/18/20
15:48
Conference/Events
Aytu BioScience to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DVA

DaVita

$79.45

0.43 (0.54%)

15:32
01/18/20
01/18
15:32
01/18/20
15:32
Conference/Events
DaVita to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, NFLX

Netflix

$339.56

0.89 (0.26%)

08:47
01/18/20
01/18
08:47
01/18/20
08:47
Periodicals
Peacock's pricing might be 'killer feature,' Barron's says »

This week, Peacock…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

, WMT

Walmart

$114.93

-0.96 (-0.83%)

08:36
01/18/20
01/18
08:36
01/18/20
08:36
Periodicals
Casper IPO highlights tech's promise, troubles, Barron' says »

Mattresses have been…

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

WMT

Walmart

$114.93

-0.96 (-0.83%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 18

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:12
01/18/20
01/18
08:12
01/18/20
08:12
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$324.11

-7.89 (-2.38%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.76

-0.14 (-1.01%)

VWAGY

Volkswagen

$0.00

(0.00%)

FSLR

First Solar

$53.51

-0.42 (-0.78%)

AAPL

Apple

$318.66

3.33 (1.06%)

DQ

Daqo New Energy

$53.61

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/17/20
01/17
16:30
01/17/20
16:30
Options
Preliminary option volume of 28.7M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.